SG11201908465QA - Substituted indoline derivatives as dengue viral replication inhibitors - Google Patents

Substituted indoline derivatives as dengue viral replication inhibitors

Info

Publication number
SG11201908465QA
SG11201908465QA SG11201908465QA SG11201908465QA SG 11201908465Q A SG11201908465Q A SG 11201908465QA SG 11201908465Q A SG11201908465Q A SG 11201908465QA SG 11201908465Q A SG11201908465Q A SG 11201908465QA
Authority
SG
Singapore
Prior art keywords
leuven
international
dengue viral
compounds
janssen
Prior art date
Application number
Other languages
English (en)
Inventor
Dorothée Alice Marie-Eve Bardiot
Bart Rudolf Romanie Kesteleyn
Jean-François Bonfanti
Pierre Jean-Marie Bernard Raboisson
Arnaud Didier M Marchand
Original Assignee
Janssen Pharmaceuticals Inc
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Univ Leuven Kath filed Critical Janssen Pharmaceuticals Inc
Publication of SG11201908465QA publication Critical patent/SG11201908465QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11201908465Q 2017-03-31 2018-03-29 Substituted indoline derivatives as dengue viral replication inhibitors SG11201908465QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17164045 2017-03-31
PCT/EP2018/058077 WO2018178238A1 (fr) 2017-03-31 2018-03-29 Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue

Publications (1)

Publication Number Publication Date
SG11201908465QA true SG11201908465QA (en) 2019-10-30

Family

ID=58464339

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908465Q SG11201908465QA (en) 2017-03-31 2018-03-29 Substituted indoline derivatives as dengue viral replication inhibitors

Country Status (31)

Country Link
US (1) US11179368B2 (fr)
EP (1) EP3601225B1 (fr)
JP (1) JP7038733B2 (fr)
KR (1) KR102556222B1 (fr)
CN (1) CN110612284B (fr)
AR (1) AR111315A1 (fr)
AU (1) AU2018246299A1 (fr)
BR (1) BR112019019928A2 (fr)
CA (1) CA3055260A1 (fr)
CL (1) CL2019002744A1 (fr)
CO (1) CO2019010292A2 (fr)
CR (1) CR20190447A (fr)
DK (1) DK3601225T3 (fr)
EA (1) EA201992334A1 (fr)
EC (1) ECSP19070413A (fr)
ES (1) ES2887673T3 (fr)
HR (1) HRP20211102T1 (fr)
HU (1) HUE055576T2 (fr)
IL (1) IL269657A (fr)
JO (1) JOP20180026A1 (fr)
LT (1) LT3601225T (fr)
MA (1) MA48987A (fr)
MX (1) MX2019011608A (fr)
NI (1) NI201900098A (fr)
PE (1) PE20191652A1 (fr)
PH (1) PH12019502095A1 (fr)
SG (1) SG11201908465QA (fr)
SI (1) SI3601225T1 (fr)
TW (1) TW201900610A (fr)
UY (1) UY37646A (fr)
WO (1) WO2018178238A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
SG11201808270PA (en) 2016-03-31 2018-10-30 Janssen Pharmaceuticals Inc Substituted indoline derivatives as dengue viral replication inhibitors
SI3436435T1 (sl) 2016-03-31 2021-08-31 Janssen Pharmaceuticals, Inc. Substituirani derivati indolina kot zaviralci replikacije virusa denga
JP7007290B2 (ja) 2016-04-01 2022-01-24 ヤンセン ファーマシューティカルズ,インコーポレーテッド デングウイルス複製阻害剤としての置換インドール化合物誘導体
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AU2018274100B2 (en) 2017-05-22 2022-06-23 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
IL270727B2 (en) 2017-05-22 2023-03-01 Janssen Pharmaceuticals Inc Transduced indulin derivatives as inhibitors of dengue virus replication
CN109485596A (zh) * 2018-12-19 2019-03-19 山东理工职业学院 一种含吲哚啉的登革病毒抑制剂的制备方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021559A1 (fr) 1997-10-27 1999-05-06 Eli Lilly And Company PROMEDICAMENTS D'ESTER DE MORPHOLINO-N-ETHYLE D'INHIBITEURS INDOLIQUES DE sPLA¿2?
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
JP2005520795A (ja) 2001-12-12 2005-07-14 コンフォーマ・セラピューティクス・コーポレイション Hsp90阻害活性を有するプリン類似体
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
CN101103026A (zh) 2005-01-14 2008-01-09 健亚生物科技公司 用于治疗病毒感染的吲哚衍生物
CA2597213A1 (fr) 2005-02-09 2006-09-14 Migenix Inc. Compositions et methodes permettant de traiter ou de prevenir les infections par les flaviviridae
BRPI0909985A2 (pt) 2008-06-03 2015-08-25 Siga Technologies Inc Composição farmacêutica e método para o tratamento ou profilaxia de uma infecção viral ou doença associada à mesma
US8143259B2 (en) 2008-08-19 2012-03-27 Janssen Pharmaceutica, Nv Cold menthol receptor antagonists
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
WO2010091413A1 (fr) 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Dérivés du dibenzimidazole liés
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
US7948798B1 (en) 2009-07-22 2011-05-24 Marvell International Ltd. Mixed multi-level cell and single level cell storage device
PT2523951E (pt) 2010-01-15 2015-09-14 Gilead Sciences Inc Inibidores de vírus flaviviridae
US20130023532A1 (en) 2010-03-26 2013-01-24 Casillas Linda N Indazolyl-pyrimidines as kinase inhibitors
JP5716205B2 (ja) 2011-03-29 2015-05-13 学校法人日本大学 グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
DK3060547T3 (en) 2013-10-23 2018-01-15 Janssen Sciences Ireland Uc CARBOXAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATMENT OF HEPATITS B
EP3988549A1 (fr) 2014-01-31 2022-04-27 Bristol-Myers Squibb Company Macrocycles avec des groupes p2' hétérocycliques en tant qu'inhibiteurs du facteur xia
CA2958022A1 (fr) 2014-10-01 2016-04-07 Janssen Pharmaceuticals, Inc Indoles monosubstitues ou disubstitues utilises en tant qu'inhibiteurs de la replication du virus de la dengue
RS58461B1 (sr) 2014-10-01 2019-04-30 Janssen Pharmaceuticals Inc Mono- ili di-supstituisani derivati indola kao inhibitori replikacije virusa denge
NO2721243T3 (fr) 2014-10-01 2018-10-20
JOP20150335B1 (ar) * 2015-01-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) * 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PT3370698T (pt) 2015-11-03 2022-03-02 Zoetis Services Llc Compósitos de polímero sol-gel e utilizações dos mesmos
SI3436435T1 (sl) 2016-03-31 2021-08-31 Janssen Pharmaceuticals, Inc. Substituirani derivati indolina kot zaviralci replikacije virusa denga
CN109715613B (zh) 2016-03-31 2021-07-30 武田药品工业株式会社 杂环化合物
SG11201808270PA (en) 2016-03-31 2018-10-30 Janssen Pharmaceuticals Inc Substituted indoline derivatives as dengue viral replication inhibitors
WO2017167832A1 (fr) 2016-04-01 2017-10-05 Basf Se Composés bicycliques
CA3018986A1 (fr) 2016-04-01 2017-10-05 Signal Pharmaceuticals, Llc Composes aminopurine substitues, compositions correspondantes, et procedes de traitement les utilisant
MY201207A (en) 2016-04-01 2024-02-09 Amgen Inc Chimeric receptors to flt3 and methods of use thereof
CN109328074A (zh) 2016-04-01 2019-02-12 凯德药业股份有限公司 嵌合抗原和t细胞受体及使用的方法
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JP7007290B2 (ja) 2016-04-01 2022-01-24 ヤンセン ファーマシューティカルズ,インコーポレーテッド デングウイルス複製阻害剤としての置換インドール化合物誘導体
CR20210084A (es) 2016-04-01 2021-03-26 Amgen Inc Receptores quiméricos y métodos de uso de los mismos (divisional 2018-0480)
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AU2018274100B2 (en) 2017-05-22 2022-06-23 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
IL270727B2 (en) 2017-05-22 2023-03-01 Janssen Pharmaceuticals Inc Transduced indulin derivatives as inhibitors of dengue virus replication

Also Published As

Publication number Publication date
UY37646A (es) 2018-09-28
CN110612284A (zh) 2019-12-24
EP3601225A1 (fr) 2020-02-05
HRP20211102T1 (hr) 2021-10-29
CN110612284B (zh) 2023-10-31
CL2019002744A1 (es) 2019-12-27
JP7038733B2 (ja) 2022-03-18
ES2887673T3 (es) 2021-12-27
BR112019019928A2 (pt) 2020-04-22
TW201900610A (zh) 2019-01-01
DK3601225T3 (da) 2021-08-16
AR111315A1 (es) 2019-06-26
MX2019011608A (es) 2019-11-08
PH12019502095A1 (en) 2020-03-09
US11179368B2 (en) 2021-11-23
LT3601225T (lt) 2021-08-10
EP3601225B1 (fr) 2021-06-02
PE20191652A1 (es) 2019-11-07
CA3055260A1 (fr) 2018-10-04
WO2018178238A1 (fr) 2018-10-04
JOP20180026A1 (ar) 2019-01-30
SI3601225T1 (sl) 2021-09-30
MA48987A (fr) 2020-02-05
HUE055576T2 (hu) 2021-12-28
EA201992334A1 (ru) 2020-02-20
NI201900098A (es) 2020-03-11
JP2020512374A (ja) 2020-04-23
US20200054606A1 (en) 2020-02-20
CO2019010292A2 (es) 2019-10-09
IL269657A (en) 2019-11-28
KR102556222B1 (ko) 2023-07-14
KR20190135496A (ko) 2019-12-06
CR20190447A (es) 2019-11-13
ECSP19070413A (es) 2019-10-31
AU2018246299A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201908786VA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201808270PA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201808138YA (en) Substituted indole derivatives as dengue viral replication inhibitors
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201908740VA (en) Sustained release delivery systems comprising traceless linkers
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201809751XA (en) Egfr inhibitor compounds
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201903889TA (en) Crenolanib for treating flt3 mutated proliferative disorders associated mutations
SG11201900633XA (en) Piperidine cxcr7 receptor modulators